EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial

Soo Heon Kwak iD, KyungWan Min, Bon Jeong Ku iD, Ji A Seo iD, Sang Yong Kim iD, Sang Youl Rhee iD, Gyuri Kim, Jae Hyoung Cho, Sang-Ah Chang iD, Sung Hee Choi, Seung Jin Han, Jeong Hyun Park iD und 14 weitere

Journal of Diabetes Investigation · 14.11.2026

DOI: 10.1111/jdi.70491 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 14.11.2026. Verfasst von Soo Heon Kwak und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine and Seoul National Universit…. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Handok.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

This study investigated the efficacy and safety of teneligliptin as an add‐on therapy in Korean patients with type 2 diabetes inadequately controlled with empagliflozin and metformin. Materials and Methods In this multicenter, double‐blind, randomized, placebo‐controlled phase 3 trial, participants with glycated hemoglobin (HbA1c) levels 7.0–10.5% treated with empagliflozin 10 mg plus metformin (≥1,000 mg/day) were randomly assigned to receive teneligliptin 20 mg once daily ( n = 116) or placebo ( n = 119). The primary endpoint was the change in HbA1c from baseline at week 24, and secondary endpoints included changes in fasting plasma glucose (FPG), achievement rate of target HbA1c, and metabolic parameters.

Results

At week 24, the teneligliptin group showed a significant reduction in HbA1c compared with the placebo group (least‐squares mean difference −0.69%; 95% confidence interval −0.83 to −0.54; P < 0.0001). The proportion of participants achieving HbA1c < 7.0% was significantly higher in the teneligliptin group (59.5% vs 21.9%; P < 0.0001). Teneligliptin also resulted in significant reductions in FPG and glycated albumin compared with placebo. The treatment was well tolerated, with no significant difference in the incidence of treatment‐emergent adverse events between the groups.

Discussion

The addition of teneligliptin to empagliflozin and metformin therapy resulted in a significant improvement in glycemic control with a favorable safety profile in Korean patients with type 2 diabetes inadequately controlled with the dual therapy. Teneligliptin can be a viable option for patients who do not achieve adequate glycemic control with empagliflozin and metformin.

Schlagwörter

Stichwörter der Autor:innen

Type 2 diabetes mellituscombination drug therapyteneligliptin

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University School of Medicine, Gwangju, Korea.
  • Department of Endocrinology and Metabolism, Kyung Hee University Hospital, Seoul, Korea.

ORCID-Profile: Soo Heon Kwak, Bon Jeong Ku, Ji A Seo, Sang Yong Kim, Sang Youl Rhee, Sang-Ah Chang, Jeong Hyun Park, Kyu Jeung Ahn, Hyuk-Sang Kwon, Sin Gon Kim, Sang Soo Kim, Jun Sung Moon, BokJin Hyun, Kyong Soo Park

Förderung

  • Handok

Zitieren

APA

Kwak, S. H., Min, K., Ku, B. J., Seo, J. A., Kim, S. Y., Rhee, S. Y., Kim, G., Cho, J. H., Chang, S. A., Choi, S. H., Han, S. J., Park, J. H., Ahn, K. J., Ahn, C. W., Cha, B. S., Kim, H. S., Nam, J. Y., Jin, H. Y., Kwon, H. S., …, & Park, K. S. (2026). Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70491

Vancouver

Kwak SH, Min K, Ku BJ, Seo JA, Kim SY, Rhee SY, et al. Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70491

BibTeX
@article{Kwak2026,
  author = {Kwak, Soo Heon and Min, KyungWan and Ku, Bon Jeong and Seo, Ji A and Kim, Sang Yong and Rhee, Sang Youl and Kim, Gyuri and Cho, Jae Hyoung and Chang, Sang-Ah and Choi, Sung Hee and Han, Seung Jin and Park, Jeong Hyun and Ahn, Kyu Jeung and Ahn, Chul Woo and Cha, Bong-Soo and Kim, Hye Soon and Nam, Joo Young and Jin, Heung Yong and Kwon, Hyuk-Sang and Kim, Sin Gon and Kim, Sang Soo and Moon, Jun Sung and Park, Kang Seo and Hyun, BokJin and Kim, SunYoung and Park, Kyong Soo},
  title = {Efficacy and safety of teneligliptin as add‐on therapy in patients with type 2 diabetes treated with empagliflozin and metformin: A 24‐week, randomized, double‐blind, placebo‐controlled phase 3 trial},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70491}
}
Kostenlos starten →